The world’s leading, full-service
ophthalmic research organization

Think Ophthalmology. Think Ora.
Learn more about what we do   Accelerate your product development

The vision and experience to guide your product development

47

Product approvals

100

Therapeutic Area Leaders with 15+ years of ophthalmic experience

96%

Clinical Project Managers with 5+ years of experience

92%

Clinical Monitors with 5+ years of experience

1,600+

Clinical studies and consulting projects

200+

Employees across 16 different countries

Our Services

Therapeutic Areas

CRO Services

Recent News

September, 2019
Spotlight on Blepharitis
Read More
November, 2018
Ora®, Inc. has been retained by ProQR Therapeutics to provide mobility test services using the Ora-VNC™ for the QR-110 development program for Leber’s Congenital Amaurosis Type 10
Read More
November, 2018
2CTech: A Case Study in a Retina Start-Up
Read More
October, 2018
Will the Evolving Economic Landscape for Dry Eye Products Impact Investment?
Read More
October, 2018
Keith Lane Discussing Ora’s Standardized Mobility Course (Ora-VNC™)
Read More
June, 2018
Presbyopia Therapies Announces Primary Safety and Efficacy Endpoints met in a Phase IIb study of its Topical PRX Ophthalmic Solution for the Treatment of Presbyopia
Read More
March, 2018
Ora, Inc. Unifies its Clinical Environment with Veeva to Accelerate Trial Execution
Read More
November, 2017
TopiVert demonstrates proof of concept in Phase 1/2a study of TOP1630 in the treatment of dry eye syndrome
Read More
September, 2017
Making Basic Science Studies in Glaucoma More Clinically Relevant: The Need for a Consensus
Read More
June, 2017
Veeva Vault CTMS Gains Momentum as Industry Moves to Unify Clinical Applications and Processes
Read More
May, 2017
Nicox receives FDA approval of ZERVIATE (cetirizine ophthalmic solution) 0.24%
Read More
May, 2017
Recognizing Additional Value in China
Read More
Dry Eye: Beyond the Usual Suspects
Read More
Ora presented 16 posters at this year’s ARVO
Read More
April, 2017
Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production
Read More
March, 2017
AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye Indications
Read More
February, 2017
Ocular Gene Therapy Trials Advance
Read More
January, 2017
Okogen Secures Ora to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis
Read More
January, 2017
Okogen Secures Ora® to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis
Read More
December, 2016
Convertible Financing 101 for the Entrepreneur
Read More
Cutting and Splicing For CRISPR Vision
Read More
December, 2016
Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis
Read More
November, 2016
Accommodation For the Aging Eye
Read More
October, 2016
Right Between Your Eyes
Read More
October, 2016
Visual Function Biomarkers Needed for Dry AMD
Read More
September, 2016
Objective: Symptomatic Assessment Strategies
Read More
August, 2016
Site Selection Success
Read More
August, 2016
How Do You Quantify The Qualitative?
Read More
Alcaftadine superior in reducing itching from grass, tree pollens
Read More
August, 2016
An Interdisciplinary Approach to Addressing an Unmet Need
Read More
July, 2016
SkQ1 Ophthalmic Solution for Dry Eye Treatment
Read More
The Impact Study
Read More
July, 2016
Allergan Files Application to FDA for Approval of Oculeve Intranasal Tear Neurostimulator
Read More
July, 2016
The Hottest Topics From ARVO 2016
Read More
ARVO 2016 meeting paves path for personalized medicine
Read More
June, 2016
Combination Therapies: Recipes for Success
Read More
June, 2016
ADVANCES IN THERAPY FOR DRY AMD
Read More
May, 2016
Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol® for the Treatment of Moderate to Severe Dry Eye Disease
Read More
May, 2016
Choosing and Planning Your Exit Strategy
Read More
May, 2016
RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye
Read More
May, 2016
An Informed Patient is A Better Patient
Read More
The Form and Function Of Meibomian Glands
Read More
April, 2016
Ora Appoints David Hollander, M.D., M.B.A., As Chief Medical Officer
Read More
April, 2016
Clinical Studies in Ocular Imaging
Read More
April, 2016
Understanding Blue Light
Read More
April, 2016
Caring for the Eye’s Gatekeepers
Read More
Diagnosing dry eye: It’s now a fine art
Read More
March, 2016
Ora Names Simon Chandler to Lead Regulatory And Clinical Operations In Europe
Read More
March, 2016
Ora presenting 11 posters at this year’s ARVO conference
Read More
March, 2016
What clinicians should know about ocular allergies
Read More
March, 2016
Oxidative Stress Reduction for Dry Eye
Read More
February, 2016
Wintering with Ocular Allergies
Read More
Physician-Entrepreneur: From Concept to Development
Read More
Nicox out-licenses OTC asset AC-120 to Ora, Inc.
Read More
February, 2016
Novaliq Begins Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease
Read More
February, 2016
Ocular Drug Delivery: Targeting the Posterior Segment
Read More
January, 2016
Neuropathic Pain: The Artifice of Dry Eye
Read More
December, 2015
Ocular Drug Delivery
Read More
December, 2015
Working Magic with Pharmacokinetics
Read More
November, 2015
It’s the Thought that Counts
Read More
Bring Them to Tears With Your Treatment
Read More
Interpreting Clinical Trial Results
Read More
November, 2015
Ora-CAC® Model Delivers Successful Phase 3 Data for Ocular Therapeutix’s DEXTENZA™ (OTX-DP) for Treatment of Allergic Conjunctivitis
Read More
November, 2015
Allergan Enters Into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment
Read More
November, 2015
Clinical Trials at Our Fingertips: A Salute to Technology
Read More
October, 2015
The Hows and Whys of Pharmacokinetics
Read More
Delving into the Dry-Eye Pipeline
Read More
A Glance at Retina Presentations at ARVO 2015
Read More
Dr. Abelson rows at the Head of the Charles Regatta
Read More
October, 2015
Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis
Read More
September, 2015
Should You Participate in Clinical Research?
Read More
New Balance Reach the Beach Relay
Read More
RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259
Read More
September, 2015
‘Tis the season to be red-eyed
Read More
Challenges faced in clinical trials for chronic allergic conjunctivitis
Read More
September, 2015
Breaking Down the Enigma of Dry Eye
Read More
August, 2015
ARVO 2015 meeting finds connections in innovative drug delivery, therapies
Read More
August, 2015
Staying Current With Apps
Read More
August, 2015
RISC and Reward with Inhibitory RNAs
Read More
July, 2015
Speaking With Patients About Premium IOL Clinical Trials
Read More
Delivering a Rocky Mountain ARVO
Read More
June, 2015
Ocular Therapeutix™ Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis
Read More
June, 2015
The Secrets of Ocular Microbiomes
Read More
May, 2015
Advances in pharmacotherapy for allergic conjunctivitis
Read More
Another great year at ARVO.
Read More
May, 2015
Portola Pharmaceuticals Announces Collaboration With Ora, Inc. for Syk-selective Inhibitor (PRT2761) in Ophthalmic Diseases
Read More
May, 2015
Avoiding Protocol Deviations In Clinical Research
Read More
A Stepwise Approach To Acute Dry Eye
Read More
Identifying and Filling the Unmet Need
Read More
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
Read More
April, 2015
Quarterly Ora Newsletter – May 1, 2015
Read More
April, 2015
Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome
Read More
April, 2015
RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S.
Read More
April, 2015
The Logistics of Participating in Device Clinical Trials
Read More
April, 2015
Gene Therapy for Retinal Diseases
Read More
Clinical Advances in Ocular Allergy
Read More
Hopes and Hurdles for Stem Cell Therapy
Read More
March, 2015
Herantis Pharma’s Phase 2 Dry Eye study recruitment completed ahead of schedule
Read More
Anti-allergic agent alcaftadine stronger in relief of ocular itching
Read More
March, 2015
Biocube allergen chamber study to start for new therapeutic for rhinitis indication
Read More
March, 2015
Fields Medal winner Manjul Bhargava to give 2015 Commencement address, joining honorand Mark Abelson
Read More
March, 2015
Sampling New Targets for Allergy Therapy
Read More
March, 2015
An evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye
Read More
March, 2015
Funding Strategies for a Retina Program
Read More
February, 2015
The Preclinical Process: Drugs Designed for the Back of the Eye
Read More
Putting Your Contacts to Work
Read More
The Scientist-Entrepreneur as CEO
Read More
February, 2015
BioLight Reports Positive Clinical Study Findings for its TeaRx™ Diagnostic Parameters for Dry Eye Syndrome
Read More
February, 2015
Automated Grading System for Evaluation of Superficial Punctate Keratitis Associated With Dry Eye
Read More
Optimizing Reading Tests for Dry Eye Disease
Read More
January, 2015
Nicox holds successful pre-NDA meeting with FDA on AC-170 clinical package
Read More
January, 2015
The Other Side of the Cornea
Read More
January, 2015
Two Decades In Translation
Read More
January, 2015
Herantis Pharma has initiated Phase 2 study with Cis-UCA Eye Drops
Read More
January, 2015
Breaking Into the Medical Device Industry
Read More
Dry eye therapy seeks to fill unmet need in artificial tears
Read More
December, 2014
The Clinical Data Management Process
Read More
December, 2014
3,500 Years of Artificial Tears
Read More
November, 2014
Ora-CAC®Model Provided Platform for Recent Positive Phase 2 Data for Ocular Therapeutix’s OTX-DP in Allergic Conjunctivitis
Read More
October, 2014
Nicox’s shareholders approve acquisition of Aciex Therapeutics, Inc.
Read More
RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
Read More
October, 2014
Guidelines for Writing Protocols
Read More
Leveraging Ex-U.S. Deals
Read More
September, 2014
Thoughts on Healing the Wounded Cornea
Read More
September, 2014
Mimetogen Pharmaceuticals Announces Topline Results of Its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome
Read More
September, 2014
Herantis Pharma announces FDA clearance of IND for Phase 2 study of Cis-UCA Eye Drops
Read More
August, 2014
A Close Look at Pseudoexfoliation
Read More
The Basics of a Pre-IND Meeting
Read More
July, 2014
Acquisition of Boston biotech for up to $120M a ‘validation’ of Ora’s model
Read More
July, 2014
Nicox to acquire Aciex Therapeutics, Inc.
Read More
July, 2014
ARVO Comes to The City of Magic
Read More
June, 2014
Including Clinical Trials at Your Practice
Read More
Resistance Fighters: An Antibiotics Update
Read More
May, 2014
Meet Ora, A family-owned firm that’s helped bring 37 eye treatments to market
Read More
May, 2014
Blink patterns and lid-contact times in dry-eye and normal subjects
Read More
May, 2014
Innate Immunity: A Question of Balance
Read More
Investigating Treatment Options for Diabetic Macular Edema
Read More
When Does an ex-U.S. Trial Make Sense?
Read More
April, 2014
It all adds up to Ora
Read More
April, 2014
Clinical Innovations
Read More
Mitotech S.A. announces the initiation of phase ii clinical trial in dry eye patients utilizing the controlled adverse environment
Read More
Ophthalmology Innovation Summit At ASCRS 2014
Read More
April, 2014
A Recipe for Better Patient Compliance
Read More
March, 2014
Running a Tight Ship
Read More
Pediatric Studies in the Retina Space
Read More
February, 2014
Don’t Olympic curlers ever blink?
Read More
February, 2014
Wise Choices for Ocular Diagnoses
Read More
January, 2014
Systemic Rxs And Ocular AEs
Read More
December, 2013
Cool Opportunities to Modulate Nociception
Read More
So you want to run a research site?
Read More
Phases of Reactions: Keys to Diagnosis
Read More
What to do when you see red
Read More
November, 2013
20 years of research and 10,000 patients: Ora dry eye system supports two largest exits in dry eye
Read More
November, 2013
Intellectual property within the context of establishing and protecting market share
Read More
Dry-Eye Tests: Reading Is Fundamental
Read More
October, 2013
Mimetogen Pharmaceuticals Inc. Announces Initiation of a Phase 3 Clinical Trial with MIM-D3 to Treat Dry Eye Syndrome
Read More
October, 2013
The Modern Wisdom Of Clinical Models
Read More
September, 2013
What’s the Plan?
Read More
A Street-Level Look At Urban Allergy
Read More
Study Participant Retention in Clinical Trials
Read More
An update on ocular allergy trends
Read More
What considerations are there for financing?
Read More
August, 2013
Acupuncture: A Dry-Eye Therapy?
Read More
July, 2013
Bausch + Lomb Acquires Option to License New Compound to Treat Dry Eye Syndrome (DES)
Read More
July, 2013
Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye
Read More
ARVO Goes to The Emerald City
Read More
ARVO: Sight set on world-class science
Read More
June, 2013
Automated grading system for evaluation of ocular redness associated with dry eye
Read More
Alternative Therapy: Good, Bad or TBD?
Read More
May, 2013
ARVO 2013
Read More
May, 2013
When do I go to meet with FDA?
Read More
May, 2013
New Therapies: Of Kinases and Cascades
Read More
Dry Eye – Special Report
Read More
Subject Recruiting
Read More
April, 2013
Sorting Out the Stats from the Jaks
Read More
Setting Eligibility Criteria
Read More
March, 2013
Begin with the End in Mind
Read More
The Pillars of Ocular Surface Pathology
Read More
Medical Device Regulation: A Review
Read More
Ophthalmic Product Development Insights
Read More
February, 2013
Aciex Enters Into Collaborative Research Agreement with Portola to Develop Dual Syk/JAK Inhibitors for Ophthalmic Indications
Read More
February, 2013
Investigation of extended blinks and interblink intervals in subjects with and without dry eye
Read More
The Drug Development Path
Read More
February, 2013
Nobel Therapeutics And Ophthalmology
Read More
January, 2013
The interblink interval in normal and dry eye subjects
Read More
January, 2013
Bausch + Lomb Licenses New Technology with Potential to Treat Millions Affected by Ocular Redness
Read More
Glaucoma Therapeutics 2013
Read More
December, 2012
Pre-clinical models
Read More
December, 2012
Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy
Read More
December, 2012
2012: Completing the premium surgical suite picture
Read More
December, 2012
In vivo Confocal Video-Microscopy
Read More
December, 2012
Glaucoma therapeutic update
Read More
2012: Year for retina approvals
Read More
Electronic Filing, The Deadline is Approaching
Read More
Bringing the Focus To the Aqueous
Read More
Where Are We With Therapeutic Approaches for Retinal Vascular Diseases?
Read More
November, 2012
A single-center study evaluating the effect of the controlled adverse environment (CAE) model on tear film stability
Read More
November, 2012
Prime Factors of Ocular Allergy
Read More
The Antimicrobial Evolution
Read More
October, 2012
Staying Local with Blepharitis Treatment
Read More
Adopting and Adapting Imaging Tools for Clinical Use
Read More
Seeing the Future of Ocular Imaging
Read More
September, 2012
Of Biomes, Biofilm and The Ocular Surface
Read More
A Preemptive Strike
Read More
August, 2012
Ora in India
Read More
August, 2012
Clinical Trials from the Statistician’s Side: Reducing Variability
Read More
August, 2012
Combination a complication
Read More
August, 2012
Vasoconstrictors: Myths and Realities
Read More
Farewell, Fort Lauderdale
Read More
July, 2012
ARVO 2012 Gives Florida Our Best
Read More
June, 2012
Pre-Surgical Steps for Your Patient
Read More
Recruiting for Invasive Clinical Trials
Read More
June, 2012
A Patient’s View of Dry-Eye Disease
Read More
May, 2012
The Allergens of Perennial Disease
Read More
May, 2012
‘Resolving’ the Effects Of Fish Oil on the Eye
Read More
Dry Eye Brimming With Innovation
Read More
AK: Let’s Shift the Blame
Read More
April, 2012
The mechanism of a Pollinosis Diagnosis
Read More
Clinical Endpoints for Retinal Disorders
Read More
March, 2012
The Other Side of the Lens
Read More
Translating Clinical Trial Results to Practice
Read More
Spring Into Action this Allergy Season
Read More
February, 2012
Unmet need spurs research
Read More
VKC and the Allergy Rogues Gallery
Read More
Therapies offer relief to many patients
Read More
January, 2012
Treating the Problem: Fungal Keratitis
Read More
Anti-VEGF State of the Union
Read More
Acanthamoeba Creeps into the Light
Read More
November, 2011
RegeneRx Reports Positive Data with RGN-259 in Phase 2 Dry Eye Trial
Read More
November, 2011
Fungal Keratitis: The Lessons Learned
Read More
Validation and Verification of the Allergen Biocube Model with an Intranasal Corticosteroid
Read More
October, 2011
The Renaissance of Drug Delivery Systems for the Posterior Segment
Read More
September, 2011
First Patient Enrolled in SARcode Bioscience’s Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
Read More
September, 2011
Clinical Trials in the Anti-VEGF Era
Read More
August, 2011
RegeneRx completes patient recruitment in Phase 2 dry eye drug trial
Read More
August, 2011
Akorn Acquires Minority Stake in Ophthalmic Drugs Firm Aciex
Read More
July, 2011
Euclid Systems partners with Ora, Inc. for development of its novel collagen-based drug delivery system for glaucoma treatment
Read More
June, 2011
It is Time to Think About the Blink
Read More
May, 2011
Dry-Eye Studies: Beware These Pitfalls
Read More
April, 2011
The Foolish Things Patients Do
Read More
March, 2011
Glaucoma and Dry Eye: A Tough Combo
Read More
March, 2011
First Study Visit Success
Read More
August, 2007
Breaking Down the Blink
Read More
June, 2005
Methodologies for the Study of Ocular Surface Disease
Read More

Accelerate your product development with Ora

For over 40 years, Ora has been on the leading edge of ophthalmic product development. We have a track record for accelerating development timelines and have helped our clients garner 47 FDA approvals. Let’s work together to move your program forward.

Get in touch